Orbis Medicines

Orbis Medicines is a well-funded, private biotech leveraging its high-throughput nGen platform to unlock oral macrocycle therapeutics, a long-standing challenge in drug discovery. The company has assembled a world-class team and board, secured significant Series A financing, and established key collaborations to advance a pipeline initially focused on creating oral alternatives to injectable biologics. By combining massive DNA-encoded library screening, automated synthesis, and AI-driven analysis, Orbis aims to de-risk and accelerate the development of these promising molecules across multiple therapeutic areas.

nGen: A high-throughput chemistry platform combining proprietary DNA-encoded libraries (DELs), automated synthesis, a full suite of assays, and machine learning/AI to systematically design, make, and test 'nCycles'—oral macrocycle drug candidates optimized for bioavailability and permeability.

Orbis competes in the emerging field of synthetic macrocycle and cyclic peptide drug discovery, facing other platform companies like Bicycle Therapeutics, Ensemble Therapeutics, and companies like Nested Therapeutics. Its differentiation lies in its specific focus on high-throughput exploration for oral bioavailability and its integrated AI/automation approach. Large pharmaceutical companies with internal macrocycle efforts are also potential competitors and partners.